Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Hepion Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Hepion Pharmaceuticals, Inc.

HEPA CTRVP

Hepion Pharmaceuticals, Inc.

About Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals is a biopharmaceutical company focused on developing therapies for liver diseases, particularly NASH and liver fibrosis. Its lead candidate, rencofilstat, is a cyclophilin inhibitor with potential to treat liver fibrosis, hepatitis, and related conditions. The company advances drug candidates through preclinical and clinical trials, seeking regulatory approval, with no current commercialization capabilities, relying on strategic partnerships and funding to support development.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Hepion Pharmaceuticals, Inc.

1
1
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals Reports $810K Net Loss in Q1 2026, Focuses on R&D

Via official filing (AI summary) | 25 days ago | 0 comments

2
1
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals Reports $8.3 Million Net Loss for Fiscal Year 2025, Faces Financial Challenges

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals Reports Q3 2025 Financial Results with Reduced Losses and Strategic Shift to Diagnostics

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals Reports Improved Q2 2025 Net Loss of $1.04 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals Reports $6.1 Million Net Loss and Strategic Developments in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals Reports $13.2 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals Reports Significant Financial Decline in 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments